Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy
| العنوان: | Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy |
|---|---|
| المؤلفون: | Bootsma, B.T., Plat, V.D., Brug, T. van de, Huisman, D.E., Botti, M., Boezem, P.B. van den, Bonsing, B.A., Bosscha, K., Dejong, C.H.C., Groot-Koerkamp, B., Hagendoorn, J., Harst, E. van der, Hingh, I.H. de, Meijer, V.E. de, Luyer, M.D., Nieuwenhuijs, V.B., Pranger, B.K., Santvoort, H.C. van, Wijsman, J.H., Zonderhuis, B.M., Kazemier, G., Besselink, M.G., Daams, F., Dutch Pancreatic Canc Grp |
| المساهمون: | Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM), Surgery, MUMC+: MA Heelkunde (9), RS: NUTRIM - R2 - Liver and digestive health, Plastic, Reconstructive and Hand Surgery, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, CCA - Cancer Treatment and Quality of Life, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism |
| المصدر: | Pancreatology, 22(3), 421-426. ELSEVIER Pancreatology, 22(3), 421-426. ELSEVIER SCIENCE BV Pancreatology, 22, 3, pp. 421-426 Pancreatology, 22(3), 421-426. Elsevier Pancreatology, 22(3), 421-426. S. Karger AG Pancreatology, 22, 421-426 Dutch Pancreatic Cancer Group 2022, ' Somatostatin analogues for the prevention of pancreatic fistula after open pancreatoduodenectomy : A nationwide analysis ', Pancreatology, vol. 22, no. 3, pp. 421-426 . https://doi.org/10.1016/j.pan.2022.03.006Test |
| بيانات النشر: | ELSEVIER SCIENCE BV, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | PROPHYLACTIC OCTREOTIDE, PHARMACOKINETICS, SURGERY, Endocrinology, Diabetes and Metabolism, INTERNATIONAL STUDY-GROUP, Somatostatin analogues, Octreotide, Pancreaticoduodenectomy, Pancreatic Fistula, Postoperative Complications, SDG 3 - Good Health and Well-being, Risk Factors, Humans, Pancreas, COMPLICATIONS, Hepatology, Pancreatoduodenectomy, Gastroenterology, Postoperative Pancreatic Fistula, Lanreotide, EFFICACY, CANCER, Pasireotide, RESECTIONS, Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10], DEFINITION, Somatostatin |
| الوصف: | Contains fulltext : 251560.pdf (Publisher’s version ) (Open Access) BACKGROUND: Somatostatin analogues (SA) are currently used to prevent postoperative pancreatic fistula (POPF) development. However, its use is controversial. This study investigated the effect of different SA protocols on the incidence of POPF after pancreatoduodenectomy in a nationwide population. METHODS: All patients undergoing elective open pancreatoduodenectomy were included from the Dutch Pancreatic Cancer Audit (2014-2017). Patients were divided into six groups: no SA, octreotide, lanreotide, pasireotide, octreotide only in high-risk (HR) patients and lanreotide only in HR patients. Primary endpoint was POPF grade B/C. The updated alternative Fistula Risk Score was used to compare POPF rates across various risk scenarios. RESULTS: 1992 patients were included. Overall POPF rate was 13.1%. Lanreotide (10.0%), octreotide-HR (9.4%) and no protocol (12.7%) POPF rates were lower compared to the other protocols (varying from 15.1 to 19.1%, p = 0.001) in crude analysis. Sub-analysis in patients with HR of POPF showed a significantly lower rate of POPF when treated with lanreotide (10.0%) compared to no protocol, octreotide and pasireotide protocol (21.6-26.9%, p = 0.006). Octreotide-HR and lanreotide-HR protocol POPF rates were comparable to lanreotide protocol, however not significantly different from the other protocols. Multivariable regression analysis demonstrated lanreotide protocol to be positively associated with a low odds-ratio (OR) for POPF (OR 0.387, 95% CI 0.180-0.834, p = 0.015). In-hospital mortality rates were not affected. CONCLUSION: Use of lanreotide in all patients undergoing pancreatoduodenectomy has a potential protective effect on POPF development. Protocols for HR patients only might be favorable too. However, future studies are warranted to confirm these findings. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1424-3903 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8215f8b38c760d512c0337de7f76f1c1Test https://doi.org/10.1016/j.pan.2022.03.006Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8215f8b38c760d512c0337de7f76f1c1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14243903 |
|---|